Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.

Antibiotic use in early adulthood, middle age ups risk of urinary stone disease in later life

17 Oct 2019

Using antibiotics for at least 2 months in early adulthood and middle age poses an increased risk of developing urinary stone disease in later life, a study suggests.

The study included 5,010 women in the Nurses' Health Study (NHS) I and II who had available 24-hour urine samples. Researchers examined the use of antibiotics during the age range of 40–49 years (NHS II), 40–59 years (NHS I) and 20–39 years (both cohorts) in relation to the incidence of symptomatic urinary stone disease and urine composition.

Cumulative use of antibiotics for 2 months during the age range of 40–49 years (NHS II) and 40–59 years (NHS II) was associated with significantly elevated risk of developing incident stones compared with no use (pooled hazard ratio [HR], 1.48, 95 percent CI, 1.12–1.96). A similar pattern of association was observed for the period of 20–39 years (pooled HR, 1.36, 1.00–1.84).

The results were consistent in an analysis excluding participants who reported urinary tract infection with their stone event or as the most common reason for antibiotic use.

Urine composition was not significantly different across antibiotic groups except for marginally lower urine pH and citrate values among those taking antibiotics for 2 months.

The study had several limitations, including the observational design, lack of information for type of antibiotic used, and relatively wide span of time between antibiotic use and urine collection.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.
11 Jan 2020
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.